Almost 26% of people with Type 1 diabetes in the U.S. rationed their insulin in the past year, a rate that is 4 times higher than other people who have the disease and live in other affluent countries, according to a survey from the nonprofit diabetes advocacy group T1 International.
Pfizer buys Array BioPharma for $11.4 billion
Pfizer has agreed to buy Array BioPharma for $48 per share, or $11.4 billion after including Array's debt. Array had never traded above $30 per share before this acquisition.
The bottom line: This is another deep-pocketed move into cancer medicines from a Big Pharma company. Array already is selling 2 FDA-approved drugs for melanoma, and Pfizer is banking on Array's other in-progress therapies to treat patients with colon cancer.